54 completed, 12 terminated, 5 unknown, 4 withdrawn. 81 Phase 2, 8 Phase 1, 6 Phase 3.
Follow Urinary Bladder, Overactive: new trials by email Literature Review of Urinary Bladder, Overactive trials Research Report on Urinary Bladder, Overactive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RELIEVE Study: NT 201 Intravesical Administration Using Vibe System (ViXe Combination Product) for the Treatment of Idiopathic Overactive Bladder NT 201 200U and Vibe System, NT 201 300U and Vibe System, Placebo and sham - Overactive Bladder (OAB) | Phase 2 | Recruiting | Vensica Therapeutics Ltd. | 210 | 2026-08-14 | 2026-10-16 |
| Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy Urodynamics, EG110A, Patient-reported Outcome - Urinary Bladder, Overactive, Spinal Cord Injury | Phase 1 / Phase 2 | Not yet recruiting | Cyllene Therapeutics | 16 | 2026-04-01 | 2025-11-12 |
| Zinc Supplementation With Botulinum Toxin for Overactive Bladder Zinc Citrate Oral Capsule, Placebo - Overactive Bladder (OAB) | Phase 2 | Recruiting | Endeavor Health | 72 | 2026-02-26 | 2026-07-02 |
| Evaluate the Safety and Efficacy of TRG-200 KIT in Patients With Refractory Overactive Bladder. TRG-200 KIT - Overactive Bladder (OAB) | Phase 2 | Not yet recruiting | Trigone Pharma Ltd. | 60 | 2026-02-15 | 2026-02-06 |
| Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder Extended release torsemide, Immediate release torsemide, Extended release torsemide placebo - Heart Failure, Overactive Bladder | Phase 2 | Completed | Sarfez Pharmaceuticals, Inc. | 24 | 2024-06-15 | 2026-03-12 |
| A Trial Evaluating the Clinical Efficacy and Safety of Hibero SR (Mirabegron) 50 mg and Ditropan (Oxybutynin Chloride) 10 mg in Children Between 5 and 18 Years With Overactive Bladder (OAB) Mirabegron 50 MG, Oxybutynin Chloride 5 MG - Overactive Bladder | Phase 2 | Unknown | Seoul National University Hospital | 44 | 2024-04-01 | 2024-03-08 |
| Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms OnabotulinumtoxinA - Urinary Incontinence, Overactive Bladder Syndrome | Phase 2 / Phase 3 | Active not recruiting | Northwestern University | 66 | 2023-07-13 | 2026-10-13 |
| Reduced-dose Botox for Urgency Incontinence Among Elder Females Botox 50 Unit Injection, Botox 100 Unit Injection - Overactive Bladder, Urinary Incontinence in Old Age | Phase 1 / Phase 2 | Active not recruiting | Dartmouth-Hitchcock Medical Center | 376 | 2023-05-12 | 2026-02-03 |
| Lidocaine Patches Prior to Percutaneous Nerve Evaluation Lidocaine patch, Placebo - Overactive Bladder, Urge Incontinence | Phase 2 | Completed | University of Louisville | 39 | 2023-05-01 | 2025-02-03 |
| Urinary Microbiome Changes Following Administration of 500 mg of NDS-446 in Women With Dry OAB at 12 Weeks 500 mg NDS-446 - Overactive Bladder | Phase 2 | Completed | Loyola University | 53 | 2023-01-01 | 2026-06-17 |
| Beta 3 Agonists in Treatment of Non-neurogenic Voiding Dysfunction in Children Beta3-Agonists, Adrenergic, Anticholinergic drug, Solifenacin - Voiding Disorders, Overactive Bladder | Phase 1 / Phase 2 | Unknown | Mansoura University | 70 | 2022-02-01 | 2022-02-15 |
| Clinical Study to Evaluate the Treatment Effect and Safety of BAY1817080 in Patients With Overactive Bladder (OAB) Placebo, BAY1817080 - Overactive Bladder | Phase 2 | Completed | Bayer | 99 | 2020-09-16 | 2022-12-22 |
| NOGO for an Overactive Bladder extract from Angelica archangelica leaf, Placebo - Overactive Bladder, Nocturia | Phase 2 | Unknown | SagaNatura | 200 | 2020-05-01 | 2020-11-12 |
| URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence URO-902, Placebo - Overactive Bladder With Urge Urinary Incontinence | Phase 2 | Completed | Urovant Sciences GmbH | 80 | 2019-12-16 | 2023-04-20 |
| Comparison of Solifenacin and Mirabegron in Treatment of Overactive Bladder Symptoms in Men After TURP Solifenacin 5Mg, Mirabegron 50 MG - Overactive Bladder Syndrome | Phase 2 | Unknown | Buddhist Tzu Chi General Hospital | 130 | 2018-08-01 | 2018-08-24 |
| A Therapeutic Exploratory Clinical Study of DA-8010 in Patients With Overactive Bladder DA-8010 Placebo, DA-8010 2.5mg, DA-8010 5mg - Overactive Bladder | Phase 2 | Completed | Dong-A ST Co., Ltd. | 306 | 2018-07-10 | 2020-02-07 |
| A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001) Solabegron modified release tablets, low dose, Solabegron modified release tablets, high dose, Matching Placebo - Overactive Bladder | Phase 2 | Completed | Velicept Therapeutics, Inc. | 1413 | 2018-07-09 | 2020-03-02 |
| Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women Solabegron immediate release tablets, low dose, Solabegron immediate release tablets, high dose, Matching Placebo - Overactive Bladder | Phase 2 | Completed | Velicept Therapeutics, Inc. | 438 | 2018-02-19 | 2020-03-02 |
| Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder. TAC-302, Placebo - Detrusor Underactivity, Overactive Bladder | Phase 2 | Completed | Taiho Pharmaceutical Co., Ltd. | 195 | 2017-09-09 | 2025-01-20 |
| Mirabegron For Erectile Dysfunction Mirabegron - Erectile Dysfunction, Overactive Bladder | Phase 1 / Phase 2 | Completed | Johns Hopkins University | 20 | 2017-08-01 | 2021-01-05 |
Showing 20 of 81. Sign in to see all of them.
Urinary Incontinence (17) · Urinary Incontinence, Urge (12) · Spinal Cord Injuries (5) · Lower Urinary Tract Symptoms (3) · Multiple Sclerosis (2) · Nocturia (2) · Urologic Diseases (2) · Cognitive Dysfunction (1) · Erectile Dysfunction (1) · Fecal Incontinence (1) · Heart Failure (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Male Urogenital Diseases (1) · Meningomyelocele (1)
Female Urogenital Diseases (81) · Female Urogenital Diseases and Pregnancy Complications (81) · Pathological Conditions, Signs and Symptoms (81) · Urogenital Diseases (81) · Male Urogenital Diseases (80) · Signs and Symptoms (80) · Urinary Bladder Diseases (80) · Urological Manifestations (80) · Urologic Diseases (79) · Lower Urinary Tract Symptoms (78) · Urination Disorders (25) · Urinary Incontinence (8) · Nervous System Diseases (7) · Central Nervous System Diseases (5) · Spinal Cord Diseases (5)
Botulinum Toxins, Type A (13) · Tolterodine Tartrate (9) · Solifenacin Succinate (7) · mirabegron (7) · incobotulinumtoxinA (5) · fesoterodine (3) · abobotulinumtoxinA (2) · casopitant (2) · darifenacin (2) · oxybutynin (2) · solabegron (2) · 1-(6-ethoxy-5-(3-ethyl-6,7-dihydro-2-(2-methoxyethyl)-7-oxo-2H-pyrazolo(4,3-d)pyrimidin-5-yl)-3-pyridyl sulphonyl)-4-ethylpiperazine (1) · Adrenergic beta-3 Receptor Agonists (1) · Cholinergic Antagonists (1) · DA-8010 (1)
Buddhist Tzu Chi General Hospital (5) · Pfizer (5) · Allergan (3) · Bayer (3) · GlaxoSmithKline (3) · Ono Pharmaceutical Co., Ltd. (3) · Astellas Pharma Europe B.V. (2) · Astellas Pharma Inc (2) · Loyola University (2) · Sanofi (2) · University of Zurich (2) · UroGen Pharma Ltd. (2) · Velicept Therapeutics, Inc. (2) · APOGEPHA Arzneimittel GmbH (1) · American Oriental Bioengineering, Inc. (1)
United States (33) · Germany (13) · France (10) · Czechia (9) · Netherlands (9) · Poland (9) · United Kingdom (9) · Canada (8) · Spain (8) · Belgium (7) · Sweden (7) · Taiwan (7) · Israel (5) · Italy (5) · Japan (5)
Hann-Chorng Kuo, M.D. (5) · Adrian S Wagg, MD (1) · Ahmed El-Zawahry, MD (1) · Alan J Wolffe, PhD (1) · Alvin Chandra, MD (1) · Ami Sidi, Prof MD (1) · Amy Krambeck, MD (1) · Angelo E Gousse, MD (1) · Anne C Cooper, MD, MA (1) · Arthur L Burnett, M.D., M.B.A. (1)
PMID 37160401, PMID 23218404, PMID 26423260, PMID 12559262, PMID 12811491, PMID 16460875, PMID 17049716, PMID 18584946, PMID 19648387, PMID 19941278, PMID 20384395, PMID 20639026, PMID 20674149, PMID 20804630, PMID 22036776, PMID 22047020, PMID 22174279, PMID 22258963, PMID 22278835, PMID 22464310, PMID 22748867, PMID 23076891, PMID 23424164, PMID 23741373, PMID 24371246, PMID 24515544, PMID 24612659, PMID 25006228, PMID 25623739, PMID 26049866, PMID 26210757, PMID 26663687, PMID 26824901, PMID 26962083, PMID 27214047, PMID 28150436, PMID 28196724, PMID 28486927, PMID 30661513, PMID 31233095, PMID 31930360, PMID 32317321, PMID 32791124, PMID 32945735, PMID 34036621, PMID 34978027, PMID 34988092, PMID 36205739, PMID 36892754, PMID 37811598
2019 (1), R01NR012011 (1)